金斯瑞生物科技(01548.HK):章方良獲委任為非執行董事
格隆匯5月3日丨金斯瑞生物科技(01548.HK)發佈公吿,章方良博士已獲委任為公司非執行董事,自2022年5月2日起生效。董事會風險管理委員會及董事會戰略委員會成立後,章博士亦獲委任為風險管理委員會及戰略委員會主席。
董事會已成立風險管理委員會,以(其中包括)支持董事會檢討公司風險管理及內部控制系統的有效性,自5月2日起生效。非執行董事章博士已獲委任為風險管理委員會成員及主席;獨立非執行董事郭宏新先生及獨立非執行董事潘九安先生已獲委任為風險管理委員會成員,自5月2日起生效。
董事會已成立戰略委員會,以(其中包括)檢討公司的中長期發展戰略並向董事會作出推薦,自5月2日起生效。董事會非執行董事章博士已獲委任為戰略委員會成員及主席;非執行董事潘躍新先生及非執行董事王佳芬女士已獲委任為戰略委員會成員,自5月2日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.